SCHEMBL2835631

SCHEMBL2835631

COc1cc(C)c(S(=O)(=O)N2CCC[C@H]2COc2nccc(N3CCC(O)(c4ccccn4)CC3)n2)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CASP3 P42574 12/20 0.35
CASP7 P55210 8/20 0.35
CASP1 P29466 3/20 0.35
CASP6 P55212 3/20 0.35
CASP2 P42575 1/20 0.35
CASP4 P49662 1/20 0.35
CASP9 P55211 1/20 0.35
CASP8 Q14790 1/20 0.35
RAB9A P51151 2/20 0.35
RET P07949 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836668 0.98 ALDH1A1 (0.40) PDE10AKDM4EALDH1A1LMNAMAPT
SCHEMBL2834813 0.87 LMNA (0.43) PDE10AALDH1A1LMNACASP3CASP7
SCHEMBL2839272 0.87 SIGMAR1 (0.37) LMNACASP3CASP7CASP1CASP6
SCHEMBL2835269 0.87 CASP3 (0.37) PDE10AALDH1A1CASP3CASP7CASP1
SCHEMBL2839685 0.86 CASP3 (0.40) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2830988 0.85 KMT2A (0.40) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2831136 0.85 LMNA (0.42) PDE10AKDM4EALDH1A1LMNAMAPT
SCHEMBL2832792 0.85 PDE10A (0.36) PDE10AKDM4EALDH1A1LMNAMAPT
SCHEMBL2832118 0.84 CASP3 (0.38) KDM4EALDH1A1LMNAMAPTHSD17B10
SCHEMBL2834971 0.84 HTR7 (0.38) KDM4EALDH1A1LMNAMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS PDE10A 296/4885KDM4E 3383/4885ALDH1A1 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.